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Abstract—Albeit there is no doubt that histamine and its H3
receptors participate in several aspects of learning and mem-
ory, such as memory consolidation, nothing is known about
their potential involvement in memory reconsolidation. On
the basis of previous reports of pro-cognitive effects of his-
tamine H3 receptor inverse agonists (which augment hista-
mine release), we investigated to what extent the most rep-
resentative of them, thioperamide, is able to facilitate recon-
solidation of a contextually-conditioned fear memory in
C57BL/6J mice. We also examined the effects of thiopera-
mide on the stark disruptive effect that the non-competitive
N-methyl-D-aspartate (NMDA) antagonist dizocilpine (MK-
801) typically exerts on both reconsolidation and consolida-
tion. Post-training systemic injections (i.p.) of thioperamide
facilitated consolidation at 10 and 20 mg/kg and reversed
amnesia induced by an i.p. injection of 0.12 mg/kg dizocilpine
at 5, 10 and 20 mg/kg. Importantly, none of the five thiopera-
mide doses (2.5, 5, 10, 20 and 30 mg/kg) given right after
reactivation (reexposure to the context in which training took
place 48 h earlier) affected reconsolidation, whereas all sim-
ilarly given doses of dizocilpine (0.03, 0.06 and 0.12 mg/kg)
disrupted it more or less equally. By contrast, thioperamide
was able to unambiguously reverse the deficit in reconsoli-
dation induced by 0.12 mg/kg dizocilpine at 10 and 20, but not
5 mg/kg. This is the first demonstration of an involvement of
the interactive articulation between histamine and NMDA re-
ceptors in the mechanisms of memory reconsolidation,
which seems to be indifferent to an increase of brain hista-
mine per se. The results suggest a qualitatively different
participation of histaminergic signalling in the mechanisms
of reconsolidation and consolidation. The precise circuits
within which these interactions take place are yet to be
identified. © 2011 IBRO. Published by Elsevier Ltd. All rights
reserved.
Key words: consolidation, reconsolidation, thioperamide,
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Histamine is secreted by neurons exclusively located in the
hypothalamic tuberomammillary nucleus (TMN) projecting
to various brain regions such as striatum, cortex, septum,
hippocampus and amygdala. Its synthesis is realized by
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132the enzyme histidine decarboxylase (HDC) and its actions
on the brain are mediated mainly by the metabotropic
receptors H1, H2, and H3. H1 and H2 receptors are primar-
ily located post-synaptically, their activation leading to ex-
citatory effects. H3 receptors, initially described as pre-
synaptic auto-receptors regulating the release of hista-
mine, can also function as hetero-receptors inhibiting the
synthesis and release of various neurotransmitters such as
GABA, dopamine, noradrenalin, serotonin or acetylcho-
line. The TMN also receives neurons from many brain
areas such as the prefrontal cortex (glutamate), the basal
forebrain (acetylcholine), the rostral raphe (serotonin), the
ventrolatérale preoptic area (GABA) or the hypothalamus
(orexin), which can provide excitatory or inhibitory inputs
(Brown et al., 2001; Haas et al., 2008; Benarroch, 2010;
Passani and Blandina, 2011).
Histamine is involved in many physiological and be-
havioural functions, including locomotion, thermoregula-
tion, epilepsy, circadian rhythms, arousal and sleep, water
and food intake, nociception, stress and anxiety and drug
reward. There is also convincing evidence for a deep
participation of histamine in the mechanisms of learning
and memory (Haas et al., 2008; Benarroch, 2010; Berlin et
al., 2011). More precisely, an increasing number of recent
animal-model studies using not only classical imidazole-
based but also several newly-synthesized non-imidazole
histamine H3 inverse agonists strongly suggest a promot-
ng action of histamine release in several processes or
spects of learning and memory, like working memory,
eference memory, acquisition or retrieval/recall (Huang et
l., 2004; Gemkow et al., 2009; Bardgett et al., 2010; Brioni
t al., 2011).
Consolidation is another major learning-and-memory
rocess that has also received some attention in histamine
sychopharmacology. This cognitive phenomenon refers
o a process during which a labile trace, emerging after
cquisition, is gradually stabilized and converted into a
asting trace resistant to any amnesic treatment (McGaugh
nd Roozendaal, 2009). Systemic, i.c.v. and intracerebral
dministrations of histamine or agents activating the re-
ease of histamine (H3 receptor inverse agonists like thio-
eramide, A-304121 or ABT-239) often strengthen mem-
ry consolidation in aversively-reinforced instrumental
asks (De Almeida and Izquierdo, 1988; Prast et al., 1996;
lood et al., 1998; Ghi et al., 2001; Orsetti et al., 2001,





































Y. Charlier and E. Tirelli / Neuroscience 193 (2011) 132–142 133Silva et al., 2006). Additionally, histamine H3 inverse ago-
nists are able to reverse memory consolidation deficits
induced by well-known amnesic agents, such as scopol-
amine and the N-methyl-D-aspartate (NMDA) antagonist
dizocilpine, suggesting the participation of a functional in-
teraction between histamine neurotransmission and both
the acetylcholine or glutamate systems in the mechanisms
of consolidation (Molinengo et al., 1999; Orsetti et al.,
2001; Bernaerts et al., 2004).
More recently, memory reconsolidation has become
the focus of cognitive and psychobiological studies. During
this memory process, the brief retrieval of memory trace,
stored in long-term memory, can induce the return to a
labile state which is subject to change and requires de
novo protein synthesis to occur (Przybyslawski and Sara,
1997; Tronson and Taylor, 2007). Recent studies have
shown that the duration of exposure is an important deter-
minant of subsequent memory processing, short exposure
to the original learning context resulting in reconsolidation
and longer exposure to the same context leading to ex-
tinction (Suzuki et al., 2004). Reconsolidation and consol-
idation share certain mechanisms occurring within the
amygdala and the hippocampus, other mechanisms being
specific to each process (Alberini, 2005; Tronson and Tay-
lor, 2007; Nader and Einarsson, 2010). For instance, in the
basolateral amygdala, protein synthesis is necessary for
both processes, while the expression of the transcription
factor CCAAT enhancer binding protein beta (C/EBPbeta)
is essential only for reconsolidation; in the hippocampus,
protein synthesis and C/EBPbeta are required only for
consolidation, but not for reconsolidation, of a passive-
avoidance fear-memory (Alberini, 2005). In others studies,
both consolidation and reconsolidation did not occur with-
out amygdala de novo protein synthesis (Nader and Ein-
arsson, 2010). Lee and colleagues (2004) have reported a
double dissociation between contextual fear conditioning
consolidation and reconsolidation within the hippocampus,
consolidation involving brain-derived neurotrophic factor
(BDNF) but not the transcription factor Zif268, whereas
reconsolidation recruits Zif268 but not BDNF.
The major neurotransmitters such as dopamine, nor-
adrenalin, acetylcholine and GABA contribute to the un-
derpinnings of both consolidation and reconsolidation, as
indicated by several recent psychopharmacological stud-
ies (Tronson and Taylor, 2007; Diergaarde et al., 2008).
Glutamate arguably constitutes the most profoundly-in-
volved neurotransmitter in the mechanisms of consolida-
tion and reconsolidation, both processes being consis-
tently inhibited by antagonists or facilitated by positive
modulators acting on the NMDA receptor (or its subunits)
in a variety of learning-and-memory procedures in rats and
mice (see reviews by Riedel et al., 2003; Morgado-Bernal,
2011). Note that reconsolidation can also be disrupted
without consolidation being affected, as is the case for the
positive modulator of the GABAA benzodiazepine-binding
ite midazolam and the beta-adrenergic antagonist propa-
olol, suggesting the possibility of a differential involve-
ent of the corresponding receptor sites and neurotrans-itters in these memory processes (Debiec and LeDoux,
004; Bustos et al., 2006).
Curiously, there is practically no psychopharmacolog-
cal study having investigated the potential participation of
istamine, yet a major monoamine neurotransmitter, in the
echanisms of reconsolidation (Bucherelli et al., 2006).
ere, we addressed that question in a series of experi-
ents examining the effects of systemic administrations of
he classic histamine H3 receptor inverse agonist thiopera-
ide (known to augment the release of histamine) on
econsolidation and consolidation of a contextual fear
emory in mice. The establishment of such a memory,
hich depends on the integrity of the amygdaloid-hip-
ocampal complex (Kim and Jung, 2006), relies on the
airing of a footshock (the unconditioned stimulus; US)
ith a circumscribed context that subsequently becomes a
onditional stimulus (CS) eliciting on its own conditioned
reezing (CR), the natural response to the initial foot-shock
UR) in rodents. As for many learning-and-memory proce-
ures, both consolidation and reconsolidation of contextual
ear memories can readily be disrupted or facilitated by
ystemic injections of NMDA antagonists or the partial
MDA agonist D-cycloserine, respectively (Suzuki et al.,
004; Lee et al., 2006; Camera et al., 2007). Since hista-
ine H3 inverse agonists can prevent the disruptive effects
hat NMDA receptor antagonists exert on consolidation of
everal cognitive tasks, as seen above, we also examined
he interactive effects of thioperamide and the representa-
ive non-competitive NMDA antagonist dizocilpine (MK-
01) on reconsolidation. To that end, thioperamide and
izocilpine dose–response curves were established in
eparate experiments for allowing the identification of op-
imal doses to be used in the interaction experiments.
EXPERIMENTAL PROCEDURES
Animals and housing
A total of 372 experimentally naive female C57BL/6J mice, born in
the central animal farm of the University of Liège, were used (only
once). Upon arrival in our animal colony, mice were housed indi-
vidually in transparent polycarbonate cages (15 cm L33 cm
W13 cm H) whose floor was lined with pine sawdust bedding.
Food (standard pellets, Carfil Quality BVDA, Oud-Turnhout, Bel-
gium) and tap water were available ad libitum during the whole
experimentation and until their euthanasia, which took place a few
weeks later. At the beginning of the experiment, mice were aged
10–12 weeks and weighted 18–22 g. The housing room was
maintained on a 12:12 h light–dark cycle (lights on at 08.00 h) with
an ambient temperature of 20–22 °C. All procedures were carried
out during the light period of the light–dark cycle, between 9:00
and 14:00 h. The experimental protocols have been approved by
the ethic committee on animal experimentation of the University of
Liège in accordance with the recommendations of the European
Community Council for the Ethical Treatment of Animals (EEC
Council Directive No. 86/609) and the Guidelines approved by the
European Commission (n° 2007/526/CE).
Drugs
Purchased from Sigma Aldrich, Bornem, Belgium, dizocilpine mal-
eate (MK-801) and thioperamide maleate solutions were prepared
fresh daily, both drugs being dissolved in sterile 0.9% saline in







Y. Charlier and E. Tirelli / Neuroscience 193 (2011) 132–142134and 2.5, 5, 10, 20 or 30 mg/kg thioperamide in a volume of 10
ml/kg (0.01 ml/g body weight), depending upon the experiment.
The control treatment consisted of an equal volume of saline
solution. All injections were given via the intra-peritoneal route
(i.p.).
Behavioral apparatus
Conditioned freezing was acquired and its retention tested in two
identical commercially-available chambers (MED Associates Inc.,
St. Albans, VT, USA, ENV-307W-TH) encased in sound-attenu-
ating cubicles (MED Associates Inc., ENV-021M). Ventilation fans
at the rear of the cubicles offered both air exchange and back-
ground noise (69 dB). The chambers were made of clear acrylic
glass boards in the back and ceiling, and aluminium sheets on
both sides, the front constituting a horizontally hinged door (24 cm
L20 cm W21.5 cm H). Illumination was provided by a small
white light mounted in the top centre of the right wall. The chamber
floor consisted of 23 stainless-steel rods, each 3 mm in diameter
and spaced 8 mm apart. A Programmable Microcontroller Con-
stant Current Shock Source (MED Associates Inc., ENV-414)
controlled a shock scrambler that delivered the footshock (US)
through the floor rods. The floor covered the upper surface of a
base platform that was mounted onto a precision force transducer
that generated a voltage current proportionate to any platform
displacement triggered by the mouse behavioural activity (Fitch et
al., 2002; Nielsen and Crnic, 2002). Each platform was calibrated
to a fixed displacement that produces a force of 1 g at a frequency
of 2 Hz via the Threshold Activity Monitoring Software (MED
Associates Inc., SOF-806). Stimuli presentation and data record-
ing from both chambers were controlled by a MED-PC program
(MED Associates Inc., SOF-735) via a specific interface (MED
Associates Inc., DIG-716). Freezing posture was defined as a total
absence of platform displacements, and thereby of movements
(except respiration-related ones, obviously), and was measured in
terms of percent time spent in that posture during the test session.
The chambers were cleaned with a 10% ethanol solution after
each individual testing.
Behavioral procedure
Our fear conditioning procedure was comparable to that often
utilized in rodent studies (e.g. Bustos et al., 2006). Prior to each
session, mice were weighted in the colony room and then con-
ducted by pairs on a cart to the experimental room, while remain-
ing in their home cage. Mice were tested less than 3 min later.
Immediately thereafter, mice were injected with the appropriate
treatment (within less than 45 s), replaced in their home cage and
returned to the colony room within 4–5 min. The whole procedure,
which involved two mice tested concomitantly, lasted a mere 15
min. The fear conditioning task comprised two basic phases: the
training session (acquisition) and the memory retention test ses-
sion (recall). On the training session, mice were placed into the
test chamber (whose context provided the CS) and left there for a
2 min pre-shock period, which was followed by two moderate
footshocks administered 28-s apart (2-s duration, 0.25-mA inten-
sity; US) and by a 30-s post-shock period. Freezing posture was
recorded during both pre- and post-shock periods. On the reten-
tion test session, which took place 72 h after the training session,
mice were replaced in the training chamber for a 5-min test period
during which conditioned freezing was recorded. In the experi-
ments dealing with reconsolidation, a reactivation session was
performed 48 h after the training session and 24 prior to the
retention session. The reactivation session consisted of exposing
the mouse to the training chamber for a unique short session of 2
min during which its behaviour was recorded without any foot-
shock being delivered. The psychopharmacological effects were
revealed on the retention test session, the drugs being injected
immediately after the training session in the consolidation exper- fiments or after the reactivation session in the reconsolidation
experiments.
Drug administration protocols
In the experiments concerning consolidation (Experiments 1, 2
and 3), all injections were given right after the training session. In
Experiment 1, four independent groups of 12 mice each were
injected with saline, 5, 10 or 20 mg/kg thioperamide, and in
Experiment 2 four other groups of 12 mice received saline, 0.03,
0.06 or 0.12 mg/kg dizocilpine. In Experiment 3, where the poten-
tial effects of thioperamide on dizocilpine-induced amnesia were
evaluated, four groups of 12 mice were injected with 0.12 mg/kg
dizocilpine a few seconds before receiving saline, 5, 10 or 20
mg/kg thioperamide, a fifth group receiving saline twice.
In the experiments concerning memory reconsolidation (Ex-
periments 4, 5 and 6), all injections were given right after the
reactivation session. Experiment 4 comprised six groups of 12
mice that received saline, 2.5, 5, 10, 20 or 30 mg/kg thioperamide.
Experiment 5, which comprised two sub-experiments, aimed at
reproducing the disruptive effects of dizocilpine on reconsolidation
in our laboratory setting. The first sub-experiment (Reactivation)
involved four groups of 13 mice that were injected with saline,
0.03, 0.06 or 0.12 mg/kg dizocilpine immediately after reexposure
to the training apparatus. The second sub-experiment (No reac-
tivation) was designed to ascertain the specificity of the disruptive
effects of dizocilpine found in the first sub-experiment. To that end,
four groups of eight mice were injected with saline, 0.03, 0.06 or
0.12 mg/kg dizocilpine in the colony room without being exposed
again to the testing apparatus, a procedure that did not allow
memory reactivation to occur. Experiment 6, which aimed at eval-
uating the effects of thioperamide on dizocilpine-induced deficit in
reconsolidation, involved four groups of 12 mice that were injected
with 0.12 mg/kg dizocilpine a few seconds prior to receiving saline,
5, 10 or 20 mg/kg thioperamide, a fifth group being injected with
saline twice.
Datal analysis
The reliability of the effects was evaluated by means of fixed-
model one-way analyses of variance (ANOVA), in which the mean
scores of conditioned freezing (percent time spent in freezing
posture) on the retention test were compared between the groups.
In case of significant effect, subsequent Tukey–HSD tests were
performed to isolate the single between-mean significant differ-
ences. The critical level of statistical significance was convention-
ally set at P0.05. For the sake of clarity and conciseness, the
data and analyses dealing with freezing on the training and reac-
tivation sessions were not presented in the Results section, the




In Fig. 1, Panel B shows the effects of thioperamide on
conditioned freezing consolidation (Experiment 1). The
freezing values derived from the groups having received
the two highest doses of the histamine H3 inverse agonist
10 or 20 mg/kg) were significantly greater than that of the
aline group, from which the effect induced by the lowest
hioperamide dose did not statistically differ. Overall, thio-
eramide tended to induce a dose-dependent increase in
emory performance, the values of the three drugged
roups remaining statistically comparable. This profile of ef-







cilpine groups), as yielded by post-ANOVA Tukey-HSD tests.
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0.048 and 20 mg/kg at P0.0012).
Panel C in Fig. 1 depicts the disruptive effects of dizo-
ilpine on conditioned freezing consolidation (Experiment
). The freezing values derived from the three groups
aving been injected with the NMDA antagonist were
tarkly smaller than the control value (saline), with no
etween-group obvious differences, a profile of effects that
as supported by the one-way ANOVA (F(3,44)39.13,
P0.0001) and Tukey–HSD between-mean comparisons
(all differences at P0.0002).
Fig. 2 (Panel B) presents the interactive effects of
thioperamide and dizocilpine administered immediately af-
ter training on conditioned freezing consolidation (Experi-
Fig. 2. Experiment 3: Effects of thioperamide on dizocilpine-induced
deficit in consolidation of a contextually-conditioned fear memory in
C57BL/6J mice. (Panel A) Diagram explaining the protocol used in this
experiment. Mice were trained under two foot-shocks (0.25 mA) that
induced reliable freezing behaviour. Dizocilpine (0.12 mg/kg) and thio-
peramide (at one of the three possible doses) were injected i.p. a few
seconds apart and immediately after completion of training, a 5-min
retention test taking place 72 h later. Memory performance was ex-
pressed in terms of percent time spent freezing (conditioned freezing
response). The control groups received saline twice or dizocilpine plus
saline. (Panel B) Interactive effects of dizocilpine and thioperamide on
consolidation as revealed by memory performance on the retention
test (n12). Columns represent meansstandard error of the mean
(vertical bars). a: value significantly different from that of the saline-
plus-saline group at P0.0004, b: value significantly different from that
of the saline-plus-dizocilpine group at P0.0043 (5 mg/kg) or
P0.0002 (10 and 20 mg/kg), as yielded by post-ANOVA Tukey-HSDFig. 1. Effects of the histamine H3 inverse agonist thioperamide and
the non-competitive NMDA antagonist dizocilpine on consolidation of a
contextually-conditioned fear memory in C57BL/6J mice. (Panel A)
Diagram explaining the protocol used in this experiment. Mice were
trained under two foot-shocks (0.25 mA) that induced reliable freezing
behaviour. The drug (at one of the three doses) or saline (n12) was
injected i.p. immediately after completion of training, a 5-min retention
test taking place 72 h later. Memory performance was expressed in
terms of percent time spent freezing (conditioned freezing response).
(Panel B) Experiment 1: Memory performance on the retention test in
thioperamide-treated mice (n12). (Panel C) Experiment 2: Memory
performance on the retention test in dizocilpine-treated mice (n12).
Columns represent meansstandard error of the mean (vertical bars).
a: values significantly different from that of the respective saline group
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received 5, 10 or 20 mg/kg thioperamide after dizocilpine
were significantly greater than that of the group treated
with dizocilpine plus saline, reaching the levels of the
control group that received saline twice (intact memory
performance), as supported by the one-way ANOVA
(F(4,55)9.52, P0.0001) and Tukey–HSD tests (5 mg/kg
at P0.0043 or 10 and 20 mg/kg at P0.0002). Note that
the decrease in memory performance in mice having re-
ceived 0.12 mg/kg dizocilpine plus saline was significant at
P0.0004.
Effects on reconsolidation
Fig. 3 (Panel B) represents conditioned freezing on the
retention test in mice having received one of the five doses
of thioperamide (2.5–30 mg/kg) immediately after the re-
activation session (Experiment 4). There was no significant
change in memory performance in any of the five groups,
which exhibited comparable values, an unambiguous ab-
sence of efficacy is corroborated by the one-way ANOVA
(F(5,78)0.322, P0.89).
Fig. 3. Experiment 4: Effects of the histamine H3 inverse agonist
thioperamide on reconsolidation of a contextually-conditioned fear
memory in C57BL/6J mice. (Panel A) Diagram describing the protocol
used. Mice were trained under two foot-shocks (0.25 mA) that induce
reliable freezing behaviour. Forty-eight hours later, thioperamide (at
one of the five possible doses) or saline were given i.p. immediately
after a 120-s reactivation session. A 5-min retention test was con-
ducted 24 h later and memory performance was expressed in terms of
percent time spent freezing (conditioned freezing response). (Panel B)
Memory performance on the retention test in thioperamide-treatedt
mice (n12). Columns represent meansstandard error of the mean
(vertical bars). There were no visible drug effects.Panel B in Fig. 4 depicts conditioned freezing on the
retention test in mice having received one of the three
doses of dizocilpine (0.03, 0.06 or 0.12 mg/kg) immediately
after the reactivation session (Experiment 5, first sub-ex-
periment). While being indistinguishable, the values from
the three experimental groups having received 0.03, 0.06
or 0.12 mg/kg dizocilpine were significantly lower than that
of the saline group, a profile of effects supported by the
one-way ANOVA (F(3,48)13.12, P0.0001) and post hoc
Tukey-HSD tests (0.03 mg/kg at P0.0012; 0.06 mg/kg at
P0.0002 and 0.12 mg/kg at P0.0003). Panel C in Fig. 4
shows the mean levels of conditioned freezing on the
retention test performed 24 h following the administration
of 0.03, 0.06 and 0.12 mg/kg dizocilpine outside of the
experimental context with the aim to control for the spec-
ificity of the effect reported in the first sub-experiment
(Panel B). Such a specificity was ascertained since the
four groups exhibited graphically undistinguishable levels
of freezing, the one-way ANOVA yielding no significant
between-group differences at all (F(3,28)0.261, P0.85).
Fig. 5 (Panel B) depicts the interactive effects of thio-
eramide and dizocilpine administered after the reactiva-
ion session on conditioned freezing as measured on the
etention test session (Experiment 6). The values derived
rom the groups having received the two higher doses of
hioperamide (10 and 20 mg/kg) right after dizocilpine
0.12 mg/kg) were significantly greater than that of the
roup treated with dizocilpine plus saline (decreased mem-
ry retention), without however reaching the levels of the
ontrol group that had received saline twice (intact memory
etention), as supported by the one-way ANOVA (F(4,55)
.99, P0.0001) and Tukey-HSD tests (10 mg/kg value at
0.0055 and 20 mg/kg value at P0.022). Note that the
alue derived from the group having received the smallest
ose of thioperamide (5 mg/kg) after dizocilpine remained
ignificantly lower than that of the group having received
aline twice (Tukey-HSD at P0.0016), which was ob-
iously significantly higher than that of the group treated
ith 0.12 mg/kg dizocilpine plus saline (Tukey-HSD at
0.0004).
DISCUSSION
The present study brought about the following findings.
Experiments 1 and 4 showed that histamine H3 inverse
gonist thioperamide convincingly facilitated memory con-
olidation but had no significant effect on reconsolidation
f conditioned fear memory in mice, even at relatively high
oses. By contrast, in Experiments 3 and 6 thioperamide
eadily abolished the disruption of both consolidation and
econsolidation induced by a representative dose of the
on-competitive NMDA antagonist dizocilpine. The disrup-
ive effects of dizocilpine per se were characterized prior to
hese experiments (Experiments 2 and 5), replicating and
omplementing previous comparable results obtained in
ats and mice tested for contextual fear memories (Suzuki
t al., 2004; Lee et al., 2006; Camera et al., 2007). Note
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given outside of the test context.
The thioperamide-induced improvement of consolidation
is the first that had been obtained using the contextual fear
conditioning procedure in the mouse. A relevant previous
study also reports similar effects in rats having received a
systemic administration of proxyfan, an H3 receptor protean
agonist (Baldi et al., 2005). We have reproduced these
results and observed a facilitation of fear-motivated pas-
sive avoidance after systemic injections of GT2231, an-
other protean agonist, in the mouse (unpublished results).
Given that protean agonists have a spectrum of activity
ranging from full inverse agonism to full agonism depend-
ing on the level of the H3 receptor constitutive activity, and
that inverse agonists typically enhance consolidation in
rodents (whatever the cognitive test), one can logically
consider that proxyfan and GT2231 acted as full inverse
agonists in those experiments (Arrang et al., 2007). In fact,
the present data are in line with a number of studies in
which post-training systemic injections of imidazole and
non-imidazole histamine H3 receptor inverse agonists fa-
cilitated the subsequent expression of passive-avoidance
fear memories (which are partially related to Pavlovian
Fig. 4. Experiment 5: Effects of the NMDA antagonist dizocilpine on
(Panel A) Diagram describing the protocols used in the two sub-exper
under two foot-shocks (0.25 mA) that induce reliable freezing behaviou
given i.p. immediately after a 120-s reactivation session (“Reactivation
sub-experiment), a 5-min retention test being conducted 24 h later. M
freezing (conditioned freezing response). (Panel B) “Reactivation” sub-
dizocilpine right after a reactivation session (n13). (Panel C) “No re
having received dizocilpine without reactivation (n8). Columns repre
different from that of the saline group at P0.0012 (0.03 mg/kg), P
ukey-HSD tests. There were no visible drug effects in the No reactivconditioned fear) and non-aversive social- or place-recog- 2nition memories in mice and rats (Prast et al., 1996; Ghi et
al., 1998; Molinengo et al., 1999; Orsetti et al., 2001; Fox
et al., 2003, 2005; Bernaerts et al., 2004). As indicated in
the introduction, the effects of systemic histaminergic com-
pounds on reconsolidation have not been examined to
date. In a study examining retrieval, that is thought to share
some functional features with reconsolidation, H3 receptor
gonists injected prior to the retention test of a contextually
onditioned fear response were found to deteriorate mem-
ry performance, an interference that was readily pre-
ented by thioperamide (Yokoyama et al., 2009). The in-
fficacy of thioperamide on reconsolidation contrasts with
he facilitation that many H3 receptor inverse agonists
ypically exert not only on consolidation but also on acqui-
ition and retrieval of aversively, positively and non-rein-
orced tasks in mice and rats (Meguro et al., 1995; Ghi et
l., 1998; Yates et al., 1999; Fox et al., 2003, 2005; Es-
enshade et al., 2005; Komater et al., 2005; Ligneau et al.,
007; Brioni et al., 2011).
Our thioperamide and dizocilpine interactive effects on
onsolidation extend to pure Pavlovian contextual fear
onditioning, comparable to previous findings obtained in
ice tested in passive avoidance task (Bernaerts et al.,
idation of a contextually-conditioned fear memory in C57BL/6J mice.
at involved either a reactivation or no reactivation. Mice were trained
ight hours later, dizocilpine (at one of the three doses) or saline were
periment) or in the colony room without reactivation (“No reactivation”
rformance was expressed in that test in terms of percent time spent
nt: Memory performance on the retention test in mice having received
” sub-experiment: Memory performance on the retention test in mice
ansstandard error of the mean (vertical bars). a: value significantly









































Y. Charlier and E. Tirelli / Neuroscience 193 (2011) 132–142138ously for reconsolidation, it has also been demonstrated
for other memory phases like acquisition, retrieval and
working memory in a variety of tasks (Chen et al., 1999;
Orsetti et al., 2001; Huang et al., 2003, 2004; Nishiga and
Kamei, 2003; Bardgett et al., 2009, 2010).
Taken together, our and some previous findings sug-
est that fear-memory reconsolidation and consolidation
re underpinned by dissimilar histaminergic mechanisms
hile sharing common interactive histamine–NMDA mech-
nisms. Concerning the substrate of these mechanisms, a
umber of studies suggests that histamine signalling is
nvolved in consolidation within both the hippocampus and
he amygdala and in reconsolidation solely or mainly within
Fig. 5. Experiment 6: Effects of thioperamide on dizocilpine-induced
deficit in reconsolidation of a contextually-conditioned fear memory in
C57BL/6J mice. (Panel A) Diagram explaining the protocol used in this
experiment. Mice were trained under two foot-shocks (0.25 mA) that
induced reliable freezing behaviour. Forty-eight hours later, mice re-
ceived i.p. injections of dizocilpine (0.12 mg/kg) and thioperamide (at
one of the three possible doses) a few seconds apart and immediately
after a 120-s reactivation session, a 5-min retention test taking place
24 h later. The control groups received saline twice or dizocilpine plus
saline. Memory performance was expressed in terms of percent time
spent freezing (conditioned freezing response). (Panel B) Interactive
effects of dizocilpine and thioperamide on reconsolidation as revealed
by memory performance on the retention test (n12). Columns rep-
resent meansstandard errors of the mean (vertical bars). a: value
significantly different from that of the saline-plus-saline group at
P0.0004 (salinedizocilpine) or P0.0016 (5 mg/kg), b: value sig-
nificantly different from that of the saline-plus-dizocilpine group at
P0.0055 (10 mg/kg) or P0.022 (20 mg/kg), as yielded by post-
NOVA Tukey-HSD tests.he hippocampus. Note that owing to the enormous com-lexity of histamine networks and differential actions of
istamine receptors, administration of comparable hista-
inergic drugs can induce both promoting and inhibitory
ognitive effects, which anyway can only logically reflect
ome functional involvement of the manipulated sites
Passani et al., 2007). Specifically, thioperamide bilaterally
nfused into the basolateral amygdala after reactivation
as been reported to remain without effect on the recon-
olidation of contextual fear memory in the rat, as in the
resent study (Bucherelli et al., 2006). By contrast, con-
olidation of contextual fear memory was hampered by
imilar infusions of thioperamide and clobenpropit (another
3 receptor inverse agonist) and improved by the H3 ag-
onist imetit (Passani et al., 2001; Cangioli et al., 2002).
Consistent with these results, consolidation of active-
avoidance fear memories can be ameliorated by post-
acquisition infusions of H1 receptor antagonists or H3 re-
ceptor agonists into the nucleus basalis magnocellularis, a
region strongly connected to the amygdala (Privou et al.,
1999). As far as we know, the reconsolidation effects of
hippocampal infusions of histaminergic drugs have not
been examined yet. Nonetheless, consolidation of contex-
tual and passive-avoidance fear memories have been re-
ported to be enhanced following dorso-hippocampal infu-
sions of H3 receptor agonists in the rat (Giovannini et al.,
2003; Da Silva et al., 2006). Consolidation can also be
impaired by ventro-hippocampal infusions of histamine in
rats tested in an active-avoidance fear conditioning proce-
dure (Alvarez and Banzan, 2008). Additionally, infused into
the medial septum, which strongly projects to the hip-
pocampus via cholinergic and GABAergic septo-hip-
pocampal neurons, thioperamide can facilitate and imetit
can blunt, both the consolidation of a similar task (Flood et
al., 1998). Several of the above-described effects were
counteracted by systemic or local applications of H1 or H2
receptor antagonists.
The available results on the cognitive involvement of
histamine–NMDA interactions within the amygdaloid–hip-
pocampal complex concern exclusively retrieval, acquisi-
tion and working memory assessed in aversively and es-
pecially positively reinforced instrumental tasks in the rat.
Nevertheless, one can reasonably conceive that these
results also hold for both consolidation and reconsolida-
tion. For instance, bilateral dorso-hippocampal infusions of
NMDA receptor agonists attenuated the retrieval deficit of
a radial-maze task induced by a systemic injection of an H1
receptor antagonist, an effect that was exacerbated by an
H3 receptor agonist (Nakazato et al., 2000; Masuoka and
amei, 2009; Masuoka et al., 2010). Conversely, bilateral
entral or dorsal hippocampal infusions of the H3 receptor
nverse agonist clobenpropit or histamine reduced radial-
aze working memory deficits induced by systemic dizo-
ilpine, and the effect of clobenpropit was reversed by an
3 receptor agonist and an H1 receptor antagonist (Huang
t al., 2003, 2004; Xu et al., 2005). In one of the few
tudies having envisaged the concomitant manipulation of
he basolateral amygdala and the ventral hippocampus,
nfusions of an H1 receptor antagonist into both these sites
































Y. Charlier and E. Tirelli / Neuroscience 193 (2011) 132–142 139an effect that was attenuated by hippocampal infusions of
glutamate (Alvarez and Ruarte, 2004). At a neurochemical
level, histamine–NMDA interactions have been evidenced
in the hippocampus and the prefrontal cortex, no compa-
rable information being available about how the amygdala
could be involved in those interactions. For instance, his-
tamine can amplify NMDA currents and synaptosomes
glutamate release in cultured hippocampal neurons (see
reviews by Brown et al., 2001; Haas et al., 2008). Impor-
tantly, histamine activation of NMDA receptors in synapto-
somes has been shown to depend, at least partly, on an
allosteric site located on these receptors, suggesting spe-
cific functions for the histamine–glutamate interactions
(Burban et al., 2010; Hansen et al., 2010).
Such a framework of fragmented results made it diffi-
ult to propose a cogent explanation of the contrast be-
ween the efficacy of thioperamide on consolidation and its
nefficacy on reconsolidation, except when combined with
izocilpine. All the more so as the histamine system is
ell-known to be functionally connected to most important
eurotransmitter systems which are deeply involved in all
hases of learning-and-memory mechanisms, albeit re-
onsolidation has been much less investigated in that re-
ard (Diergaarde et al., 2008). In fact, we are left to count-
ess speculative suggestions. For example, one can posit
hat reconsolidation of contextual fear memories normally
nvolves higher intensity of histaminergic transmission than
ther memory processes like consolidation and thus re-
uires greater doses of H3 inverse agonists to be facili-
tated. In our experiments, the smallest dose of thiopera-
mide (5 mg/kg) abrogated the disruptive effect of dizocil-
pine on consolidation but remained without effect on
dizocilpine-induced disruption of reconsolidation. Also, the
alleviating effects of the highest thioperamide doses (10
and 20 mg/kg) on dizocilpine-induced deficits in reconsoli-
dation reached levels that tended to remain lower than the
control levels (albeit the differences were far from being
significant, see Fig. 5). This hypothesis is unlikely since in
vivo cortical H3 receptor occupancy by thioperamide can
achieve quasi maximal levels at around 15 mg/kg (i.p.), our
highest dose being 30 mg/kg thioperamide (Miller et al.,
2009). Furthermore, in a study currently in progress in our
laboratory, systemic injections of a large range of doses of
highly brain-penetrating H3 receptor inverse agonists
ielded the same pattern of effects as those reported here
or thioperamide.
One can also speculate that the hampered efficacy of
oth systemic and amygdalar administrations of thiopera-
ide on reconsolidation (Bucherelli et al., 2006; present
esults) was due to relatively low H3 receptor, or even H1
and H2 receptors, availabilities in specific but still unde-
ned amygdalar circuits. However, there is no convincing
vidence for the existence of particular amygdalar subar-
as with low densities in H1, H2 and especially H3 recep-
tors, although a few studies have reported that these re-
ceptors (binding and mRNA expression) are far from being
evenly distributed over the amygdalar and hippocampal
areas (Drutel et al., 2001; Pillot et al., 2002; Lozada et al.,
2005).In another scenario, the reduced efficacy of systemic
post-reactivation thioperamide could have been induced
by thioperamide itself via the parallel mobilization of a
circuitry normally responsible for an inhibitory control of
fear expression that would have hampered an otherwise
facilitated reconsolidation, the final cognitive outcome re-
maining unchanged. Such a control can be conveyed by
the pathways projecting from the medial prefrontal cortex
to amygdalar circuits, which are thought to control the
expression and the extinction of conditioned fear (Sotres-
Bayon et al., 2004). According to recent models, during the
recall of conditioned freezing, increased output of the lat-
eral and basal nuclei of amygdala excites the central nu-
clei, thereby promoting fear expression via outputs to the
brainstem. Fear is reduced by the parallel activation of the
prefrontal cortex which in turn excites amygdalar interca-
lated inhibitory GABAergic neurons to attenuate the out-
puts of central nuclei (Sotres-Bayon et al., 2004; Kim and
Jung, 2006). Since the prefrontal cortex deep layers are
rich in H1 and H2 receptors, post-reactivation thiopera-
ide-induced histamine release could have triggered
hese inhibitory pathways and amygdalar mechanisms in-
olved in reconsolidation (Dai et al., 2007; Haas et al.,
008). Another hypothetical mechanism of concomitant
eutralization of thioperamide-induced effect on reconsolida-
ion could rely on a reduction of amygdalar ERK phosphory-
ation, whose activation within the amygdala has been shown
o facilitate reconsolidation (Tronson and Taylor, 2007). Since
3 receptor activation, which diminishes histamine release,
can facilitate ERK phosphorylation in the amygdala (Arrang
et al., 2007), one could speculate that thioperamide some-
what inhibited ERK phosphorylation cascade and thus
failed to accentuate reconsolidation in our mice and Bu-
cherelli and collaborators’ rats (2006). Naturally, such a
counteracting control could also be mediated by one or
several neurotransmitters, via undefined circuitries inside
or outside the amygdada, such as GABA, norepinephrine,
serotonin or acethylcholine, some of which being known to
be released by histamine and H3 receptors in the
amygdala, the nucleus basalis, the septum or the hip-
pocampus (Brown et al., 2001; Haas et al., 2008; Passani
et al., 2007).
It must be kept in mind that given that thioperamide
and other H3 inverse agonists are able to affect consolida-
tion when infused into the amygdala, each of the above-
described mechanistic scenarios necessarily implies that
reconsolidation and consolidation to be subtended by dis-
tinct and specialized histaminergic circuits, which are far
from being evidenced. Additionally, it is only by reactivating
dizocilpine-blocked NMDAergic neurotransmission proba-
bly via the allosteric site located on the NMDA receptor that
thioperamide-induced histamine released, at least in the
hippocampus, would have somewhat rescued reconsoli-
dation. Thus, histaminergic participation in reconsolidation
would necessarily depend upon the occurrence of some
changes in NMDA activity, whereas that involved in con-
solidation would not, both neurotransmitter systems acting
individually as well as interactively on both cognitive pro-






























Y. Charlier and E. Tirelli / Neuroscience 193 (2011) 132–142140reconcile with the findings that NMDA receptor blockade
can augment and metabotropic (mGlu) 2 receptor activa-
tion can mitigate histamine neuron activity in the mouse
and rat prefrontal cortex and especially ventral hippocam-
pus, histamine neurons expressing NMDA receptors (Fau-
card et al., 2006; Fell et al., 2010). One must admit that
dizocilpne-induced histamine activation either occurs in
brain areas that are not involved in memory mechanisms
or it is not enough to be able to influence these processes
in presence of an overwhelming NMDA receptor blockade.
In conclusion, to our knowledge the present findings
show for the first time the existence of a functional hista-
mine–NMDA/glutamate interaction underpinning contex-
tual fear reconsolidation, which is not affected by the sep-
arate pharmacological activation of the histamine system.
Contextual fear consolidation appeared to be readily facil-
itated by drug-induced histamine release both with and
without drug-induced NMDA blockade. The exact mecha-
nisms whereby H3 receptors inverse agonists exert these
ifferential effects have to wait further elucidation. In par-
icular, it remains unknown how basolateral amygdala cir-
uits could contribute to the histamine-NMDA underpin-
ings of reconsolidation. A manner to verify the hypothesis
hat amygdalar histamine is predominantly involved in the
ack of effect of thioperamide on reconsolidation would be
o repeat our reconsolidation experiment with an auditory
ear conditioning procedure that is known to be far less
ippocampus-dependent than contextual fear conditioning
Kim and Jung, 2006). In other words, if amygdalar hista-
ine activity is not involved in reconsolidation processes,
hioperamide or any other histaminergic interference with
eactivation should not affect auditory fear memory or ab-
ogate its disruption under NMDA blockade. Also, it would
e fruitful to undertake studies comparing systematically
he fear memory effects of post-acquisition (consolidation)
r post-reactivation (reconsolidation) infusions into the hip-
ocampus, the amygdala or both structures of histamine
3 inverse agonists alone or in association with NMDA
ntagonists.
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